What are the guideline‑recommended management steps for undifferentiated pleomorphic sarcoma of the breast?

Management of Undifferentiated Pleomorphic Sarcoma of the Breast

Undifferentiated pleomorphic sarcoma (UPS) of the breast should be managed as a primary breast sarcoma with wide surgical excision achieving clear margins, without axillary lymph node staging, and adjuvant radiotherapy should be strongly considered for large (>5 cm) or high-grade tumors with close or positive margins to improve local control. 1

Critical Diagnostic Distinction

Before proceeding with treatment, confirm this is a true primary breast sarcoma and not sarcomatous differentiation within a metaplastic carcinoma. If sarcomatous differentiation is present within a metaplastic carcinoma, manage as triple-negative breast cancer, not as a sarcoma 1.

Multidisciplinary Team Referral

All breast sarcomas, including UPS, must be referred to specialist sarcoma centers for pathology review and multidisciplinary team (MDT) discussion due to variation in clinical practice and improved outcomes at specialized centers 1. Close collaboration between breast cancer MDT and sarcoma MDT is essential 1.

Surgical Management Algorithm

Step 1: Initial Assessment

• Perform metastatic screening before surgery 2
• No sentinel lymph node biopsy or axillary dissection is required - this is a key difference from epithelial breast cancer, as breast sarcomas rarely metastasize to lymph nodes 1

Step 2: Surgical Approach

Standard treatment is wide excision with clear margins 1:

• Breast-conserving surgery (BCS) can be performed if:

  • Tumor can be completely excised with clear margins
  • Satisfactory aesthetic result is achievable

• Mastectomy is indicated when:

  • Large tumors where breast conservation is not possible
  • Clear margins cannot be achieved with BCS
  • For UPS specifically, given its high-grade aggressive nature, mastectomy is often necessary 3, 4

Step 3: Reconstruction Timing

Delayed reconstruction is strongly preferred over immediate reconstruction for large, high-grade UPS 1:

• Patients with large high-grade tumors will likely receive postoperative chest wall radiotherapy
• Significant risk of local recurrence exists within first two years
• Immediate reconstruction should only be considered if it will not compromise administration of adjuvant radiotherapy
• Delayed reconstruction after completion of oncological treatment and when local recurrence risk has decreased is the safer approach

Adjuvant Radiotherapy

Adjuvant radiotherapy improves local control but not survival in breast sarcomas 1. Neoadjuvant radiotherapy has no role in breast sarcomas 1.

Indications for Adjuvant Radiotherapy:

Consider adjuvant chest wall radiotherapy for 1:

• Large tumors (>5 cm) - strong indication
• Close margins (<5 mm) - strong indication
• Positive margins - strong indication
• High-grade tumors (which UPS is by definition)
• Multifocal disease
• Recurrent disease
• Apply these criteria regardless of whether BCS or mastectomy was performed

If close margins are present, attempt repeat surgical excision to achieve clear margins if feasible before proceeding to radiotherapy 1.

Chemotherapy Considerations

Adjuvant or neoadjuvant chemotherapy is NOT routinely given for breast sarcomas - this is another critical difference from epithelial breast cancer 1.

For metastatic or unresectable disease, systemic therapy options include 5:

• Pembrolizumab (for tumor mutational burden-high disease ≥10 mutations/megabases)
• Pazopanib (for patients ineligible for anthracycline-based regimens)
• Regorafenib (for nonadipocytic sarcomas)
• Doxorubicin-based regimens remain standard first-line for metastatic disease

Prognosis and Follow-up

UPS of the breast carries an aggressive prognosis 3, 6, 4:

• High risk of local recurrence even with negative margins
• Cases with lung and brain metastases suggest particularly aggressive behavior 3, 4
• Radiation-induced UPS has particularly poor prognosis (27-36% 5-year survival) 6
• Total mastectomy with negative margins and tumor-free lymph nodes may be key to improved prognosis 3

Common Pitfalls to Avoid

1. Do NOT perform axillary staging - this is unnecessary and adds morbidity without benefit
2. Do NOT give routine adjuvant chemotherapy - unlike epithelial breast cancer, this is not standard
3. Do NOT perform immediate reconstruction in large, high-grade tumors that will require radiotherapy
4. Do NOT manage as metaplastic carcinoma - confirm true sarcoma histology first
5. Do NOT skip sarcoma MDT referral - specialized review is essential for optimal outcomes